Charles G. Phillips III is Director at NovoCure Ltd (NVCR). They have made 5 open-market trades across 1 company since 2018, most recently 2019-12-02.
CIK 0001129246
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NVCR | SELL | 2019-12-02 | 2019-12-04 | $88.11 | $1.1M | -7.8% | -15.7% | -22.0% |
| NVCR | SELL | 2019-08-30 | 2019-09-03 | $91.13 | $4.0M | -9.5% | -14.3% | +0.7% |
| NVCR | SELL | 2019-05-29 | 2019-05-31 | $52.21 | $6.2M | +5.1% | +16.6% | +72.7% |
| NVCR | SELL | 2019-05-29 | 2019-05-31 | $52.17 | $5.0M | +5.1% | +16.6% | +72.7% |
| NVCR | SELL | 2018-05-25 | 2018-05-30 | $30.30 | $1.5M | -3.7% | -0.3% | +28.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.